Publications by the researcher in collaboration with Javier Cassinello Espinosa (13)

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

2020

  1. Latest progress in molecular biology and treatment in genitourinary tumours

    Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2175-2195

2019

  1. BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

    Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1

  2. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

    Oncologist, Vol. 24, Núm. 4, pp. 491-497

2017

  1. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy

    Clinical and Translational Oncology, Vol. 19, Núm. 10, pp. 1175-1182

2016

  1. Role of taxanes in advanced prostate cancer

    Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 972-980

2015

  1. Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 96, Núm. 2, pp. 308-318

2012

  1. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

    Critical Reviews in Oncology/Hematology, Vol. 83, Núm. 3, pp. 341-352

2011

  1. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 16, pp. 2433-2439

2009

  1. Prostate stem cells and cell differentiation

    Handbook of Prostate Cancer Cell Research: Growth, Signalling, and Survival (Nova Science Publishers, Inc.), pp. 211-241

  2. The role of COX-2 in prostate carcinoma: Therapeutical implications

    Handbook of Prostate Cancer Cell Research: Growth, Signalling, and Survival (Nova Science Publishers, Inc.), pp. 363-388

2003

  1. Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer

    Medical Oncology, Vol. 20, Núm. 1, pp. 37-43